In clinical trials with patients suffered from type 2 diabetes and mild cognitive impairment (MCI) and treated for 2 years with DPP4 inhibitors, i.e. vildagliptin, sitagliptin or saxagliptin, a significant improvement in cognitive activity was noted in comparison with patients treated with sulfonylureas35. This evidence concerns the gene DPP4 and Cognitive impairment.